Drugs /

abiraterone

Back to Drugs List

Overview

Generic Name(s):
abiraterone
Trade Name(s):
Zytiga
NCI Definition [1]:
A steroidal compound with antiandrogen activity. Abiraterone inhibits the enzymatic activity of steroid 17alpha-monooxygenase (17alpha-hydrolase/C17,20 lyase complex; CYP17A1), a member of the cytochrome p450 family that catalyzes the 17alpha-hydroxylation of steroid intermediates involved in testosterone synthesis. Administration of this agent may suppress testosterone production by both the testes and the adrenals to castrate-range levels.

Clinical Trials

View Clinical Trials for abiraterone

Abiraterone has been investigated in 77 clinical trials, of which 70 are open and 7 are closed. Of the trials investigating abiraterone, 2 are early phase 1 (2 open), 15 are phase 1 (11 open), 10 are phase 1/phase 2 (10 open), 34 are phase 2 (31 open), 1 is phase 2/phase 3 (1 open), 13 are phase 3 (13 open), and 2 are phase 4 (2 open).

ATM Loss, ATM Mutation, and BRCA1 Loss are the most frequent biomarker inclusion criteria for abiraterone clinical trials.

Prostate adenocarcinoma, prostate carcinoma, and malignant solid tumor are the most common diseases being investigated in abiraterone clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Abiraterone
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Abiraterone
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating abiraterone and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
Zytiga, 17-(3-pyridyl)androsta-5,16-dien-3beta-ol, 17-(3-pyridyl)androsta-5,16-dien-3beta-ol, cb-7598, cb7598, androsta-5,16-dien-3-ol, 17-(3-pyridinyl)-, (3beta)-, abiraterone, abiraterone, (3beta)-17-(pyridin-3-yl)androsta-5,16-dien-3-ol, abiraterone (substance), cb 7598
Drug Target(s) [2]:
CYP17A1
NCIT ID [1]:
C77333
SNOMED ID [1]:
R-FB403

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.